A Review of the Rationale and Clinical Utilization of α2-Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders-Reference-Cited by-同舟云学术

A Review of the Rationale and Clinical Utilization of α2-Adrenoceptor Agonists for the Treatment of Attention-Deficit/Hyperactivity and Related Disorders

Published:2013-06 Issue:5 Volume:23 Page:308-319
ISSN:1044-5463
Container-title:Journal of Child and Adolescent Psychopharmacology
language:en
Short-container-title:Journal of Child and Adolescent Psychopharmacology

Author:

Sallee Floyd¹,Connor Daniel F.²,Newcorn Jeffrey H.³

Affiliation:

1. Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio.

2. Department of Psychiatry, University of Connecticut School of Medicine, Farmington, Connecticut.

3. Department of Psychiatry, Mount Sinai School of Medicine, New York, New York.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Psychiatry and Mental health,Pediatrics, Perinatology and Child Health

Link

http://www.liebertpub.com/doi/pdf/10.1089/cap.2013.0028

Reference103 articles.

1. New Aspects of the Clinical Pharmacology of Clonidine

2. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes

3. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Therapeutic Potential of Cannabigerol in Neurodegenerative Diseases;J BIOL REG HOMEOS AG;2024

2. An expert opinion on the pharmacological interventions for Disruptive Mood Dysregulation Disorder (DMDD);Expert Opinion on Pharmacotherapy;2024-01-02

3. An updated safety review of the current drugs for managing ADHD in children;Expert Opinion on Drug Safety;2023-10-24

4. Psychostimulanzien und andere Arzneistoffe, die zur Behandlung der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) angewendet werden;Neuro-/Psychopharmaka im Kindes- und Jugendalter;2023

5. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung;Neuro-/Psychopharmaka im Kindes- und Jugendalter;2023